News | FFR Technologies | June 17, 2019

First Prospective Registry Confirms FFR Impacts CAD Treatment Plans

Global registry demonstrates fractional flow reserve provides valuable additional information after angiography, resulting in treatment changes in more than a third of patients in daily clinical practice

First Prospective Registry Confirms FFR Impacts CAD Treatment Plans

June 17, 2019 – A prospective, multicenter, multinational study examines how fractional flow reserve (FFR) can impact treatment plans and outcomes in patients with stable coronary artery disease (CAD) or acute coronary syndrome (ACS). Results showed more than one-third of the patients’ initial treatment plans changed after FFR. The findings from the global registry were presented as late-breaking clinical research at the Society for Cardiovascular Angiography and Interventions (SCAI) 2019 Scientific Sessions, May 19-22 in Las Vegas.

According to the Centers for Disease Control (CDC), CAD is the most common type of heart disease, killing more than 370,000 people a year in the United States. FFR is known to be an extremely accurate diagnostic tool for CAD and ACS patients. It offers a precise physiology technique to measure blood pressure and flow in a coronary artery, and has recently become a routine practice to help guide revascularization decisions for clinicians compared to angiography alone.

In this registry, for the first time, treatment plans for patients were recorded prospectively rather than retrospectively following angiography, prior to performing FFR. Treatment options included medical therapy, percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). Standard pre-defined clinical outcomes were also identified and recorded.

The PRESSUREwire (Practical Evaluation of Fractional Flow ReservE (FFR) and its ASsociated Alternate IndiceS DUring Routine Clinical ProcEdures) study enrolled more than 2,200 subjects across 70 hospitals in 15 countries between October 2016 and February 2018. Treatment plans based on angiography alone changed in 34 percent of patients post-FFR. Results showed approximately 5 percent more patients were planned for medical management post-FFR than post-angiography, fewer patients were assigned to PCI treatment post-FFR and more patients were assigned to CABG. There were no serious adverse events related to FFR measurement.

“Our registry data further validates numerous previous studies and reinforces the importance of using coronary physiology guidance in conjunction with angiography to guide the patient treatment plan,” said lead author Erick Schampaert, M.D., Hospital Sacre-Coeur De Montreal in Montreal, Canada. “Having accurate measurements can make a difference between a patient having an unnecessary invasive procedure or not intervening quickly enough when a patient does need further attention. Equipping physicians for better patient management has the potential to positively impact patient outcomes.”

The authors of the study note the importance of incorporating FFR in daily clinical practice and recommend interventionalists to rely less on angiography alone, when non-invasive documentation of ischemia is not available.

For more information: www.scai.org

Read more about late-breaking clinical trials at SCAI


Related Content

News | FFR Technologies

Feb. 3, 2026 — Medtronic plc announced it will exercise its option to acquire CathWorks, a privately held medical device ...

Home February 03, 2026
Home
News | FFR Technologies

Oct. 27, 2024 — HeartFlow, Inc. recently announced seven-year data confirming the use of HeartFlow’s AI-enabled ...

Home October 30, 2024
Home
News | FFR Technologies

June 4, 2024 — HeartFlow, a leader in cardiovascular healthcare technology, is pleased to announce a key Medicare policy ...

Home June 04, 2024
Home
News | FFR Technologies

May 23, 2024 — HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) heart care solutions, announced ...

Home May 23, 2024
Home
News | FFR Technologies

January 3, 2024 — HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) precision coronary care ...

Home January 03, 2024
Home
News | FFR Technologies

June 28, 2023 — CathWorks announced that the first patient has been enrolled in the Advancing Cath Lab Results with ...

Home June 28, 2023
Home
News | FFR Technologies

March 3, 2023 —CathWorks announced key events for the company during the annual American College of Cardiology (ACC) ...

Home March 03, 2023
Home
News | FFR Technologies

January 4, 2022 - Pie Medical Imaging (PMI), a global leader in cardiac imaging, part of the Esaote Group, recently ...

Home January 04, 2022
Home
News | FFR Technologies

December 13, 2021 - HeartFlow Inc., the leader in revolutionizing precision heart care, today announced it has submitted ...

Home December 13, 2021
Home
News | FFR Technologies

November 9, 2021 — The primary results of the Fractional Flow Reserve Versus Angiography for Multivessel Evaluation ...

Home November 09, 2021
Home
Subscribe Now